Dexibuprofen

Drug Profile

Dexibuprofen

Alternative Names: Daxfen; DexOptifen; Movone; S-(+)-Ibuprofen; Seractil; Ultraprofen

Latest Information Update: 20 Apr 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gebro Pharma GmbH
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Back pain; Dysmenorrhoea; Headache; Inflammation; Musculoskeletal pain; Osteoarthritis; Pain; Postoperative pain; Rheumatic disorders

Most Recent Events

  • 05 Apr 2008 Pharmacokinetics data from a Phase-I trial in healthy volunteers presented at the 109th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2008)
  • 13 Jul 2007 Madaus has been acquired by Rottapharm
  • 21 Feb 2006 Phase-III clinical trials in Postoperative pain in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top